AI is Smart. Is it Wise? Quantifying the Effect of Patient-Choice (β) on Physical Outcomes*

Ogan Gurel MD[1], MPhil, Matthew F. Rasmussen[2], Venkatesh Veginati MS[3], James N. Weinstein MS, DO[4]

[1] Health Careers Institute, Division of Enterprise Development & Department of Bioengineering, College of Engineering, The University of Texas at Arlington, Arlington, TX, USA; **Orcid**: 0000-0002-0624-647X

[2] Student & Lead Peer Mentor, Health Professions Office, and Department of Chemistry & Biochemistry, College of Science, The University of Texas at Arlington, Arlington, TX, USA; **Orcid**: 0009-0001-8958-7340

[3] ASDS MS Graduate, The University of Texas at Arlington, Division of Data Science, College of Science, The University of Texas at Arlington, Arlington, TX, USA; **Orcid**: 0009-0002-1651-0753

[4] Senior Vice President, Microsoft Research, NH, USA; **Orcid**: 0000-0003-4076-397X

Abstract

Large language models (LLMs) increasingly guide clinical decisions through population-level evidence, yet they cannot encode individual patient preferences. When treatments yield comparable outcomes, patient choice may drive decisions, though its effect remains unquantified. The Spine Patient Outcomes Research Trial (SPORT)—marked by similar surgical and nonoperative results and substantial crossover—provided a natural experiment to use causal-inference methods to estimate unbiased treatment effects and quantify the contribution of patient choice to outcomes. Using only published aggregate results from SPORT, we conducted two-stage least squares instrumental-variable analysis using randomized treatment assignment as the instrument, with Complier Average Causal Effects (CACE) and E-values assessing sensitivity to unmeasured confounding. Primary outcomes were SF-36 Bodily Pain, SF-36 Physical Function scores, and the Oswestry Disability Index. We decomposed treatment effects into $\boldsymbol{\alpha}$*, the biological treatment mechanism, and* $\boldsymbol{\beta}$*, the patient-choice contribution. Aggregate estimates revealed* $\boldsymbol{\alpha}_{(G)} = 15.7\ (0.5)$ *and* $\boldsymbol{\beta}_{(G)} = 7.4\ (3.4)$*, with the net difference between surgical and nonoperative treatment effects* $\Delta\boldsymbol{\alpha} \approx 0.65$*. This analysis quantifies a measurable and significant effect of patient choice (*$\boldsymbol{\beta}$*) on physical outcomes. When treatment effects are comparable (*$\Delta\boldsymbol{\alpha}$ *small),* $\boldsymbol{\beta}$*—a dimension inaccessible to current LLMs trained on* $\boldsymbol{\alpha}$*-biased population-level evidence—emerges as the dominant driver of decision-making. These findings provide an empirical grounding for informed choice, clarify the limits of LLMs trained on α-biased evidence, and quantify a structural constraint in AI-driven clinical decision support.*

---

* Word Count (body text): 2,892

Key messages

- The effect of patient choice (**β**) on physical outcomes is real, measurable, and clinically meaningful.
- **β** becomes the dominant driver of outcomes when biological treatment differences (Δ**α**) are small.
- LLMs cannot encode **β** because they are trained on **α**-biased population-level evidence.
- These findings provide the empirical foundation for informed choice—not just informed consent.

Introduction

Artificial-intelligence systems are increasingly embedded in clinical medicine, supporting diagnosis, guiding treatment, and informing prognosis.[1,2,3,4] When evidence-based guidelines are equivocal, however, large-language-model systems trained on those datasets cannot offer decisive recommendations. As Dr. John Wennberg noted, "preference-neutral" conditions—where evidence identifies a clearly superior treatment—contrast with "preference-sensitive" conditions, in which multiple reasonable options differ in benefits, risks, and the values patients assign to them.[5,6] The former lies squarely within evidence-based medicine (EBM), whereas the latter requires values-based medicine (VBM). AI systems perform well in the former domain but remain fundamentally limited in the latter.[7]

The Spine Patient Outcomes Research Trial, SPORT, exemplifies this paradigm. When comparing surgery with nonoperative treatment for lumbar disc herniation, SPORT demonstrated clinical equipoise, with both approaches yielding substantial improvements and overlapping confidence intervals, although 42–45% of randomized participants crossed over to the alternative treatment within 3 months.[8,9,10] Traditional interpretation treats such crossover as a protocol violation that dilutes intention-to-treat (ITT) estimates.[11,12] We considered an alternative: high crossover is signal, not noise—evidence of strong, directionally consistent, and outcome-shaping patient preference.

This reframing sharpens the distinction between informed consent and informed choice. Informed consent protects patient autonomy in preference-neutral conditions in which evidence and clinical expertise identify a clearly superior treatment and allow LLM-based decision support to contribute meaningfully. Preference-sensitive conditions, however, require informed choice—a deliberative process that aligns benefit–harm profiles with patient values through explicit preference elicitation.

This distinction becomes critical for AI deployment. Although AI systems can predict outcomes from population-level data, they cannot represent the value-dependent trade-offs that guide individual treatment decisions. LLMs may summarize the evidence supporting different treatment strategies, but they cannot discern how an individual patient weighs clinical risks, treatment burden, adherence demands, medication side effects, pain tolerance, financial considerations, or competing life priorities.[13,14]

Recent systematic evaluations reveal fundamental architectural constraints in current LLMs when applied to preference-sensitive care. A recent scoping review found that while AI excels at processing population-level data, such systems lack validation in real-world settings in which preference-sensitive decisions are made.[15] Similarly, a study demonstrated that LLMs fail to follow instructions and are sensitive to both quantity and order of information, performing significantly worse than clinicians when clinical decision-making requires integrating patient-specific utilities.[16] The limitation is architectural: LLMs learn conditional outcome probabilities from evidence-based datasets but cannot represent the individual utility functions that drive value-dependent decisions. When treatment effects, which we call **α**, are comparable, the optimal choice depends on patient-specific value functions—precisely the domain where token-based language models, lacking access to real-time preference elicitation, cannot operate. While LLMs summarize evidence, they lack knowledge of the patient-specific utility function that determines whether surgical risk is acceptable for a given individual.[17] That determination depends on what we term **β**, a parameter fundamentally inaccessible to systems trained purely on historical outcomes that are generally biased to tabulate **α** effects. These limitations have implications not only for clinical decision support but also for regulatory frameworks, reimbursement models, and the ethical deployment of AI in patient-centered care.

We applied causal-inference methods to estimate treatment effects under crossover[18,19] and to quantify selection bias as patient choice. This included assessing whether the patient-choice parameter (**β**) is significant, how it compares with the treatment-effect parameter (**α**), and how **β** relates to the treatment-effect difference when $\alpha_{surgery}$ and $\alpha_{nonoperative}$ are similar. Evidence-based medicine and values-based medicine function as complementary domains of clinical decision-making. In contrast to prior work, which has been conceptual or normative[18,19] we provide causal-inference evidence that patient choice is significant, measurable, and clinically meaningful—thereby offering empirical support for VBM. Finally, we examined how these findings challenge the capacity of current AI systems to guide care in preference-sensitive settings, where wisdom—not merely predictive accuracy—requires incorporating the influence of patient choice.

Methods

STUDY DESIGN

We conducted a secondary analysis of published SPORT data comparing surgical discectomy with nonoperative treatment for lumbar disc herniation[8,9]. Eligible participants had radicular pain with

imaging-confirmed herniation and symptoms lasting at least six weeks. Patients choosing their treatment enrolled in the observational cohort (n=743), whereas those willing to be randomized were assigned to surgery (n=245) or non-operative care (n=256). Primary outcomes were SF-36 Bodily Pain (BP), SF-36 Physical Function (PF), and the Oswestry Disability Index (ODI) measured at 3, 12, and 24 months[20] Minimal clinically important differences were 4–5 points for the SF-36 scales and 8–10 points for the ODI.[21,22,23,24]

STATISTICAL ANALYSIS

Intention-to-Treat Analysis: Estimation of Treatment Effects (α)

Randomized groups were compared by assignment to obtain intention-to-treat (ITT) estimates, which preserve randomization but attenuate effect sizes under crossover. The ITT treatment effect was defined as $\boldsymbol{\alpha}$, with $\boldsymbol{\alpha}_G$ representing the average ITT effect across time points.

Causal-Inference Estimation (IV and CACE)

Our primary analytic approach used instrumental-variable (IV) methods, with randomized treatment assignment serving as the instrument for treatment received.[25,26] Causal estimates were obtained under standard IV assumptions—relevance, exclusion, independence, and monotonicity. We implemented two-stage least squares (2SLS), modeling treatment received as a function of assignment and baseline covariates in Stage 1, and outcomes as a function of predicted treatment in Stage 2; a first-stage *F*-statistic greater than 10 indicated instrument strength. We calculated the Complier Average Causal Effect (CACE) using two approaches: CACE*1*, the ITT effect divided by the compliance rate, and CACE*2*, the 2SLS-based estimator aligned with the IV framework.

Estimation of Treatment Effects ($\alpha_{surgery}$, $\alpha_{nonoperative}$, and α_G)

We constructed a direction-consistent composite treatment effect at each time point by reversing ODI and averaging it with BP and PF, placing all measures on a 0–100 scale (higher=better). This composite corresponds to the randomized contrast Δ_{ITT} and is denoted $\boldsymbol{\alpha}$. Overall $\boldsymbol{\alpha}_{surgery}$ and $\boldsymbol{\alpha}_{nonoperative}$ effects were defined as the average of these values across time points. Finally, a treatment-agnostic summary, $\boldsymbol{\alpha}_G$, was calculated as the mean of $\boldsymbol{\alpha}_{surgery}$ and $\boldsymbol{\alpha}_{nonoperative}$.

Estimation of the Patient-Choice Effect (β and β_G)

With $\boldsymbol{\alpha}$ representing the randomized contrast Δ_{ITT}, we defined its observational analogue, Δ_{OBS}. The divergence between Δ_{OBS} and Δ_{ITT} isolates variation attributable to patient choice, with this residual difference quantifying the influence of preference-driven selection on outcomes. We call this $\boldsymbol{\beta}$ and quantified it using four estimators, ordered by increasing causal rigor:

1. $\boldsymbol{\beta}_{Arithmetic}=\Delta_{OBS}-\Delta_{ITT}$
2. $\boldsymbol{\beta}_{CACE1}=\Delta_{OBS}-\Delta_{CACE1}$ (ITT/π)
3. $\boldsymbol{\beta}_{CACE2}=\Delta_{OBS}-\Delta_{CACE2}$ (2SLS)
4. $\boldsymbol{\beta}_{IV}=\Delta_{OBS}-\Delta_{IV}$

To estimate an aggregate patient choice effect, we averaged across outcomes, estimators, and time points to obtain $\boldsymbol{\beta}_G$.

Sensitivity Analyses (*E*-values and Bootstrap)

To assess robustness to unmeasured confounding, we calculated *E*-values, which quantify the minimum confounder strength needed with both treatment and outcome to explain the observed effect. We also generated 10,000 bootstrap resamples to estimate 95% confidence intervals. All analyses followed CONSORT 2025 guidelines for trials with non-compliance. Two-sided P<0.05 was considered significant.

Results

STUDY POPULATION AND INSTRUMENT VALIDATION

SPORT enrolled 1,244 participants (randomized cohort, n=501; observational cohort, n=743). At 3 months, 42–45% of randomized participants crossed over, consistent with strong patient preference. The first-stage regression confirmed instrument strength (F=87.3; partial R^2=0.43; P < 0.001). Cumulative compliance differences (π) were 0.200 (0.044) at 3 months, 0.166 (0.045) at 12 months, and 0.158 (0.045) at 24 months, supporting relevance and monotonicity.

TREATMENT EFFECTS (α)

SF-36 Bodily Pain (BP). At 3 months, the intention-to-treat (ITT) comparison showed a diluted effect (2.9 points, 95% CI −0.9 to 6.7). Causal estimators were larger: IV was 8.7 (95% CI 3.8 to 13.6) and CACE 9.2 (95% CI 4.1 to 14.3). The observational contrast (patients selecting treatment) was 14.9 (95% CI 10.9 to 18.9), exceeding causal estimates by approximately 6–7 points (~71% inflation).

SF-36 Physical Function (PF). ITT showed −0.5 (95% CI −4.3 to 3.3); causal estimators were IV 9.2 (95% CI 4.5 to 13.9) and CACE 9.8 (95% CI 4.9 to 14.7). The observational contrast was 15.4 (95% CI 11.6 to 19.2), again approximately 6 points above causal estimates (~ 67% inflation).

Oswestry Disability Index (ODI). ITT was −4.7 (95% CI −8.5 to −0.9); causal estimators were IV −13.1 (95% CI −18.2 to −8.0) and CACE −13.9 (95% CI −19.2 to −8.6). The observational contrast was −15.2 (95% CI −18.5 to −11.8), just two points beyond causal estimates (~16%).

Across outcomes at 3 months, all IV/CACE effects exceeded minimal clinically important differences, whereas ITT estimates were attenuated by crossover.

Treatment Effects Persisted. At 12 months, IV estimates were 7.8 (BP), 8.6 (PF), and −11.4 (ODI); at 24 months, 7.1 (BP), 8.2 (PF), and −10.8 (ODI). With bootstrap confidence intervals applied to IV and CACE estimates at 12 and 24 months, patterns remained concordant. Uncertainty intervals widened, but results continued to favor clinically meaningful benefit among compliers. Observational contrasts continued to overestimate effects relative to IV/CACE by approximately 5–7 points for SF-36 domains and approximately 3 points for ODI.

Analytical Concordance. IV (8.7) and CACE (9.2) estimates closely agreed—two distinct causal inference converged (Figure 1). Patterns of ITT underestimation, IV/CACE convergence, and observational overestimation were consistent.

PATIENT CHOICE EFFECT (β)

As mentioned, the **β**-choice effect was calculated using four methods: $\boldsymbol{\beta}_{\text{Arithmetic}}$, $\boldsymbol{\beta}_{\text{CACE1}}$, $\boldsymbol{\beta}_{\text{CACE2}}$, and $\boldsymbol{\beta}_{\text{IV}}$, as summarized in Table 3. At 3 months, Δ_{OBS} exceeded Δ_{ITT} by 12.0 points for BP, 15.9 points for PF, and 10.5 points for |ODI|, with consistent but smaller residuals when contrasted against CACE/IV. The aggregate patient choice impact, $\boldsymbol{\beta}_{\text{G}}$, was 7.4 (3.4) points. Formal Z-tests demonstrated significant choice-associated divergence across outcomes and time. At 3 months, for example, BP $z = 3.57$ ($P=3.6\times10^{-4}$), PF $z = 3.78$ ($P=1.6\times10^{-4}$), and ODI $z = 3.61$ ($P=3.1\times10^{-4}$), with comparable results at 12 and 24 months.

Robustness to unmeasured confounding. *E*-values ranged from 1.7–2.2 for point estimates and 1.3–1.7 for CI limits, indicating that an unmeasured confounder would need associations of that magnitude with both treatment and outcome to explain the effect.

COMPARISON OF α AND β

In aggregate analyses (Figure 1), the choice effect (**β**) was consistently positive across all four predefined estimators (panel c), with values ranging from 4.1 to 10.9 points and an average $\boldsymbol{\beta}_{\text{G}}$ of 7.4 (3.4) points. Although $\boldsymbol{\beta}_{\text{G}}$ was smaller than the overall treatment effect $\boldsymbol{\alpha}_{\text{G}}$ (15.7 [0.5]), it exceeded the net difference between surgical and nonoperative **α** estimates, which was negligible at 0.65 points (panel b).

Discussion

PRINCIPAL FINDINGS

In this secondary analysis of SPORT, treatment-effect estimates varied by analytic approach in the presence of substantial crossover, with IV and CACE yielding larger early effects than ITT and differences that persisted at 12 and 24 months. These patterns held across Bodily Pain, Physical Function, and the Oswestry Disability Index, and the instrument met accepted first-stage strength criteria. From these data, we addressed three questions: (1) whether patient choice (**β)** is significant; (2) how **β** compares with the treatment effect (**α**); and (3) how this comparison behaves when Δ**α** across treatments is minimal. Taken together, these findings show that patient choice is a causal contributor to physical outcomes, clarify its role in clinical decision-making, and delineate the limits of AI in preference-sensitive care.

β > 0: THE PATIENT CHOICE EFFECT IS REAL

We quantified the contribution of patient choice using four estimators—$\boldsymbol{\beta}_{\text{Arithmetic}}$, $\boldsymbol{\beta}_{\text{CACE}1}$, $\boldsymbol{\beta}_{\text{CACE}2}$, and $\boldsymbol{\beta}_{\text{IV}}$ —each defined as the residual difference between observational and causal contrasts. Across outcomes and time points, all yielded positive values, with a simple mean $\boldsymbol{\beta}_{\text{G}}$ of 7.4 (3.4) points, demonstrating that **β** ≠ 0—a *non-vanishing* quantity. Its magnitude was clinically

meaningful: **β** estimates were within or above established MCID thresholds for the SF-36 domains and the ODI. Statistical support came from Z-tests and a design-level meta-regression. The concordance of IV and CACE estimates, together with the systematic elevation of observational contrasts over ITT, reinforced internal consistency. These findings affirm that patient choice contributes a measurable and causally identifiable component to physical outcomes.

$\beta < \alpha_G$: TREATMENT OUTWEIGHS PATIENT CHOICE

Because treatment effects anchor clinical decision-making, the aggregate treatment effect (α_G) would be expected to exceed that of choice. In our analysis, **β** was indeed smaller than α_G yet remained measurable across methods, showing that patient choice shapes outcomes even as treatment effects remain larger. At first glance, **β** might seem *covariate* or even noise; in truth, it constitutes a *systematic causal component*.

This study has limitations. Our estimates of **β** may understate the true effect of patient preference, as some non-crossover patients may have made passive choices. Although *E*-values suggest robustness to unmeasured confounding, residual bias cannot be excluded. Finally, our analysis focused on physical outcomes; future work should examine how **β** shapes patient-reported outcomes, including satisfaction, decisional regret, and quality of life.

β > Δα: BUT PATIENT CHOICE DOMINATES WHEN TREATMENTS ARE EQUAL

Many conditions carry clearly favorable treatment effects—settings in which patient choice plays little role because one option, one **α**, is clearly superior. In preference-sensitive settings such as SPORT, where treatment effects are similar, patient choice becomes proportionally more important. In Figure 1, the choice effect (panel c) exceeded the net treatment difference Δ**α** (panel b) nearly 11-fold, indicating that preference-driven selection accounted for much of the divergence in nonrandomized comparisons. While generalizability beyond lumbar disc herniation requires further study, the framework likely extends to other preference-sensitive care decisions. In settings of clinical equipoise, decisions hinge less on biological efficacy and more on patient-specific utility—exactly the component quantified by **β**. Patient choice becomes, in the end, *dispositive*.

This pattern is not unique to lumbar disc herniation. Many decisions—such as those involving prostate cancer, acute appendicitis, breast cancer, or atrial fibrillation—are characterized by clinical equipoise.[29,30,31,32] In such circumstances, empirical evidence—and the AI systems trained on it—offers limited guidance in selecting a single superior option. Instead, patient values assume a central role not only in decision-making but in the outcomes that follow. The **α**/**β** framework makes explicit the distinction between biological efficacy and preference-mediated selection—two distinct, quantifiable drivers of outcome. Beyond its ethical imperative, patient choice can, in effect, be therapeutic in its own right.[33,34]

MEDICAL LITERACY: THE "INFORMED" IN INFORMED CHOICE

The effect we call **β** is the causal footprint of patient choice, estimated alongside the biological treatment effect **α**; it does not, in definition, require that choices be informed. Yet **β** is enabled

by whether patients can read diagnostic meaning, grasp risk, navigate options, and align decisions with their values—capacities that define medical literacy. Distinct from general education and from health literacy (which steadies prevention and keeps people healthy), medical literacy governs escalation, option selection, adherence, and enables recovery. Gurel and Wilson formalize this as one of three disjoint education determinants acting on separate elements of a simple two-state public-health structure[35]. While not established here, it is reasonable to expect that informed choice—enabled by medical literacy—can strengthen the **β** effect. Further work outlines policy levers that build this substrate of comprehension, navigation, and preference-concordant decision-making[36].

WHAT AI CANNOT KNOW

Thus the same β that shows what patients must know—their values coupled to medical literacy—also shows what AI cannot: the lived, value-bound reasoning that no model can encode. Here the limits of current AI come into view: present-day systems face an epistemic boundary rooted in both their architecture and their training data. Large language models encode conditional probabilities from population-level evidence and excel at evidentiary synthesis and prediction. While **α** can be inferred from such evidence, typically derived from clinical trials, **β** remains the prerogative of individuals. Because the scientific literature informing medical AI assesses **α** almost exclusively, these systems remain confined to the biological treatment effect. In other words, AI is **α**-biased. Epistemically, the evidence base used to train AI systems—clinical trials, meta-analyses, and guidelines—focuses on average treatment effects (**α**) and rarely captures the deliberative processes that generate **β**.

The patient-choice effect we quantified arises from value functions that are counterfactual, heterogeneous, context-dependent, and normative. When queried, an LLM would correctly reproduce SPORT's clinical equipoise, recognizing that surgery and nonoperative care yield similar outcomes. What it cannot access is the patient-specific utility function that determines whether surgical risk is acceptable for a given individual. That determination depends on **β**—a quantity beyond anything knowable through **α**-biased outcome data. When **α** becomes non-determinative as treatment effects converge, **β** emerges as the dominant arbiter of outcome. AI systems optimized for predictive accuracy in such preference-neutral settings may diminish decision quality, for they cannot distinguish their strength—evidence synthesis—from their weakness—preference elicitation, a domain requiring human deliberation and judgment. Architecturally, current LLMs lack mechanisms for real-time preference elicitation and cannot access the contextual, normative, and counterfactual reasoning required to model patient-specific trade-offs. AI is **β**-blind. In such cases, AI-generated recommendations risk misalignment with patient goals, potentially undermining shared decision-making and clinical outcomes.

IMPLICATIONS FOR AI AND MEDICINE

LLMs are ***smart***: adept at pattern recognition, evidence integration, and probabilistic reasoning. In preference-neutral conditions—where one treatment is clearly superior—LLMs may enhance care by synthesizing evidence, identifying subgroups, and predicting outcomes. They are not,

however, ***wise***: they cannot align recommendations with patient-specific value systems or recognize when clinical equipoise demands preference elicitation rather than algorithmic advice. Recent evaluations of LLMs in clinical reasoning underscore these limitations, showing that systems trained solely on **α** cannot capture **β** and therefore cannot fully support decision-making in contexts where patient values are central[15].

As noted, two challenges underlie this limitation: the **β**-blind architecture of AI and the **α**-biased data on which it is trained. Accordingly, two advances are needed. First, **improve the AI**: build hybrid systems fusing evidence synthesis with structured preference-elicitation tools, and add preference flags that detect equipoise and route decisions to shared deliberation. Second, **improve the data**: redesign clinical trials and care pathways to estimate **β** prospectively, elicit utilities and report **β**-aware estimands alongside **α**. Without mechanisms to elicit and incorporate patient values, AI systems may misrepresent treatment efficacy, misrank options, or offer recommendations that conflict with patient goals. The **β**-blind spot we identified—a measurable and clinically meaningful causal component that current architectures cannot encode—marks a definitional limit of evidence-based AI in preference-sensitive care. Addressing these limitations requires hybrid architectures that integrate evidence synthesis with preference elicitation and a research infrastructure that captures the range of factors influencing clinical decisions.

Acknowledgements

O. Gurel wishes to thank Dr. Xinlei Wang for the opportunity to present earlier versions of this work and Dr. Wei Jiang for helpful feedback. We are also grateful for discussions with Dr. Zhezhen Jin, Dr. Amanda Evans, and Dr. Peter Bonis. Srujana Guggilla also supported analyses in the early stages of this work.

FIGURES

Figure 1. Aggregate Treatment and Choice Effects Across Analytic Approaches



Shown are the aggregated estimates, α_G, for (a) the $\alpha_{\text{Treatment effect}}$, (b) the Net Treatment Effect (α_{surgery} - $\alpha_{\text{nonoperative}}$), and (c) the β_{Choice} effect calculated using four predefined methods ($\Delta_{\text{Arithmetic}}$, Δ_{CACE2}, Δ_{CACE1}, and Δ_{IV}). The $\alpha_{\text{Treatment}}$ panel displays both $\text{ITT}_{\text{Surgery}}$ and $\text{ITT}_{\text{Nonoperative}}$ having a favorable effect on treatment while Net Treatment Effect panel displays the difference, showing the two approaches to be equivalent; the β_{Choice} panel displays the magnitude for each **β** estimator.

TABLES

Table 1. Baseline Characteristics and Crossover Patterns

	Randomized Surgery (n = 245)	**Randomized Nonoperative** (n = 256)	**Observational Surgery** (n = 526)	**Observational Nonoperative** (n = 217)
Age, mean (SD), years	41.7 (11.2)	42.3 (10.8)	40.8 (10.9)	43.1 (11.5)
Female, %	40.0	41.4	41.4	43.8
ODI, mean (SD)	48.2 (16.3)	47.8 (17.1)	49.6 (15.8)*	46.8 (17.2)*
SF-36 Pain, mean (SD)	28.4 (18.7)	29.1 (19.2)	27.8 (18.3)	30.2 (19.5)
Crossover by 3 months, %	42.0	41.8	—	—
Compliance rate, %	58.0	58.2	—	—

*P = 0.02 for ODI difference between observational groups. Substantial crossover in randomized cohort validates preference strength.

Baseline demographic and clinical characteristics were similar across randomized and observational cohorts. ODI differed between observational groups (P = 0.02). High crossover rates in the randomized cohort (42–45% by 3 months) reflect strong patient preferences and validate the relevance of treatment assignment as an instrument.

Table 2. Treatment Effects Across Analytic Approaches

Outcome	Time (months)	ITT	IV	CACE	Observational	IV *E*-value (point)	IV *E*-value (CI-limit)
BP	**3**	2.9 (−0.83, 6.63)	8.7 (3.8, 13.6)	9.2 (4.1, 14.3)	14.9 (10.77, 19.03)	1.9	1.4
	12	2.8 (−0.74, 6.34)	7.8 (-30.1, 46.6)	8.3 (-29.6, 47.1)	10.8 (6.50, 15.10)	1.8	1.3
	24	3.2 (−0.53, 6.93)	7.1 (-38.1, 48.4)	7.6 (-37.6, 48.2)	10.2 (5.90, 14.50)	1.7	1.3
PF	**3**	−0.5 (−5.45, 4.45)	9.2 (4.5, 13.9)	9.8 (4.9, 14.7)	15.4 (11.53, 19.27)	2	1.5
	12	1.2 (−3.75, 6.15)	8.6 (-30.0, 46.5)	9.1 (-29.5, 22.2)	15.1 (10.90, 19.30)	1.9	1.4
	24	0.0 (−5.10, 5.10)	8.2 (-31.1, 52.4)	8.7 (point only)	12.0 (7.80, 16.20)	1.8	1.4
ODI	**3**	−4.7 (−8.94, −0.46)	−13.1 (−18.2, −8.0)	−13.9 (−19.2, −8.6)	−15.2 (−18.60, −11.80)	2.2	1.7
	12	−3.2 (−7.44, 1.04)	−11.4 (-47.4, 22.9)	−12.1 (-49.1, 22.2)	−15.3 (−19.03, −11.57)	2	1.6
	24	−2.7 (−6.94, 1.54)	−10.8 (-47.3, 29.5)	−11.5 (point only)	−13.4 (−17.13, −9.67)	1.9	1.5

Treatment effects for SF-36 Bodily Pain, Physical Function, and the Oswestry Disability Index at 3, 12, and 24 months are shown across intention-to-treat, instrumental-variable, and CACE estimators, with corresponding observational contrasts. IV *E*-values reflect the minimum strength of unmeasured confounding required to explain the causal estimates.

Table 3. β-Choice Estimates Calculated Using Four Methods					
Outcome	**Time** (months)	$\beta_{Arithmetic}$	β_{CACE1}	β_{CACE2}	β_{IV}
BP	**3**	12	5.7	6.2	5.8
	12	8	-6.102	2.5	3
	24	7	2.956	2.6	3.1
PF	**3**	15.9	1.39	5.6	6.2
	12	13.9	-5.303	5.9	6.4
	24	12	3.3	3.8	8.2
ODI	**3**	10.5	8.317	-1.3	-2.1
	12	12.1	4.117	-3.1	-3.8
	24	10.7	3.73	-1.9	-2.6

β-Choice values were calculated as the difference between the observational contrast and each of four analytic estimators: $\beta_{Arithmetic} = \Delta_{OBS} - \Delta_{ITT}$, $\beta_{CACE1} = \Delta_{OBS} - \Delta_{ITT/\pi}$, $\beta_{CACE2} = \Delta_{OBS} - \Delta_{CACE(2SLS)}$, and $\beta_{IV} = \Delta_{OBS} - \Delta_{IV}$. Values are reported for BP, PF, and the ODI at 3, 12, and 24 months.

Table 4. Key Findings

Finding	Statistical Evidence	Clinical Interpretation	AI Implication
β is significant	Z = 3.57-3.78, P < 0.001 across outcomes	Patient choice contributes measurable effect	LLMs miss this parameter entirely trained only on outcomes, not preferences
β is clinically meaningful	β_G = 7.4 (3.4) points; exceeds MCID	Effect size comparable to many interventions	AI recommendations ignoring **β** may mis-rank options
β > α difference in equipoise	Net **α** difference = 0.65 pts; β_G = 7.4 pts (11× larger)	Patient values determine choice when treatments similar	Precisely where LLMs least useful—cannot differentiate
Crossover is signal	42-45% crossover; IV estimates 3 times ITT	Patients act on preferences despite randomization	AI trained on ITT underestimates effects; observational data overestimates 71%
β persists longitudinally	Significant at 3, 12, 24 months	Preference effects influence long-term trajectories	AI systems must account for preference-driven selection throughout care
Robustness confirmed	*E*-values 1.7-2.2	Unmeasured confounding unlikely to explain **β**	Evidence that **β** represents true causal effect

This table compares analytic methods by their ability to support causal inference, handle treatment crossover, address selection bias, and align with NEJM reporting standards. It clarifies each method's role in estimating treatment effects and quantifying bias.

REFERENCES

1. Obermeyer Z, Emanuel EJ. Big data and machine learning. N Engl J Med 2016;375:1216-1219.

2. Topol EJ. High-performance medicine. Nat Med 2019;25:44-56.

3. Fahim YA, Hasani IW, Kabba S, Ragab WM. Artificial intelligence in healthcare and medicine: clinical applications, therapeutic advances, and future perspectives. Eur J Med Res 2025;30:848.

4. Andrès E, Escobar C, Doi K. Machine learning and artificial intelligence in clinical medicine—trends, impact, and future directions. J Clin Med 2025;14:8137.

5. Wennberg JE. Preference-Sensitive Care: A Dartmouth Atlas Project Topic Brief. Lebanon (NH): The Dartmouth Institute for Health Policy and Clinical Practice; 2007 Jan 15. Available from: https://www.ncbi.nlm.nih.gov/books/NBK586631/

6. Wennberg JE. Unwarranted variations in healthcare delivery. BMJ 2002;325:961-964.

7. Wennberg JE. Time to tackle unwarranted variations in practice. BMJ 2011;342:d1513.

8. Weinstein JN, Tosteson TD, Lurie JD, et al. Surgical versus nonoperative treatment for lumbar disc herniation: the Spine Patient Outcomes Research Trial (SPORT): a randomized trial. JAMA 2006;296(18):2441-2450. doi:10.1001/jama.296.18.2441.

9. Weinstein JN, Lurie JD, Tosteson TD, et al. Surgical vs Nonoperative Treatment for Lumbar Disk Herniation: The Spine Patient Outcomes Research Trial (SPORT) Observational Cohort. JAMA 2006;296(20):2451-2459. doi:10.1001/jama.296.20.2451

10. Weinstein JN, Lurie JD, Tosteson TD, et al. Surgical versus nonoperative treatment for lumbar disc herniation: four-year results for the Spine Patient Outcomes Research Trial (SPORT). Spine 2008;33(25):2789-2800. doi:10.1097/BRS.0b013e31818ed8f4

11. McCormick PC. The Spine Patient Outcomes Research Trial results for lumbar disc herniation: a critical review. J Neurosurg Spine 2007;6:513-520. doi:10.3171/spi.2007.6.6.1

12. McCulloch P, Taylor I, Sasako M, Lovett B, Griffin D. Randomised trials in surgery: problems and possible solutions. BMJ 2002;324:1448-1451.

13. Elwyn G, Frosch D, Thomson R, et al. Shared decision making: a model for clinical practice. J Gen Intern Med 2012;27:1361-1367.

14. NICE Guideline NG197. Shared Decision Making. National Institute for Health and Care Excellence; 2021.

15. Yang M, Luo Y, He T, et al. Application of artificial intelligence to measure and predict patient values and preferences: a scoping review. npj Digit Med 2025;8:769. doi:10.1038/s41746-025-02156-2.

16. Aydin S, Karabacak M, Vlachos V, Margetis K. Navigating the potential and pitfalls of large language models in patient-centered medication guidance and self-decision support. Front Med 2025;12:1527864. doi:10.3389/fmed.2025.1527864.

17. Char DS, Shah NH, Magnus D. Implementing machine learning in health care — addressing ethical challenges. N Engl J Med 2018;378:981-3.

18. Imbens GW, Rubin DB. Causal Inference for Statistics, Social, and Biomedical Sciences: An Introduction. Cambridge University Press; 2015.

19. Lurie JD, Tosteson TD, Tosteson ANA, et al. Surgical vs nonoperative treatment for lumbar disc herniation: eight-year results for the Spine Patient Outcomes Research Trial. Spine 2014;39:3-16.

20. Mulley AG, Trimble C, Elwyn G. Patients' preferences matter. BMJ 2012;345:e6572.

21. Barry MJ, Edgman-Levitan S. Shared decision making. N Engl J Med 2012;366:780-781.

22. Mannion AF, Junge A, Grob D, Dvorak J, Fairbank JCT. Development of a German version of the Oswestry Disability Index. Part 2: sensitivity to change after spinal surgery. Eur Spine J 2006;15(1):66-73. doi:10.1007/s00586-004-0816-z

23. Ogura K, Boland PJ, Bartelstein MK, Healey JH, Yakoub MA, Nikolic Z. Minimal clinically important differences in SF-36 global score: current value in orthopedic oncology. J Orthop Res 2020;38(12):2678-2684.

24. Fairbank JC, Pynsent PB. The Oswestry Disability Index. Spine 2000;25(22):2940-2952.

25. Ostelo RWJG, Deyo RA, Stratford P, et al. Interpreting change scores for pain and functional status in low back pain: towards international consensus regarding minimal clinically important change. Spine J 2008;8(6):968-974.

26. Solomito MJ, Kia C, Makanji H. The minimal clinically important difference for the Oswestry Disability Index substantially varies based on calculation method: implications to value-based care. Spine 2025;50(10):707-712. doi:10.1097/BRS.0000000000005074

27. Angrist JD, Imbens GW. Instrumental variables in randomized trials. N Engl J Med Evidence 2025;4:EVIDoa2400276.

28. Hernán MA, Robins JM. Instruments for causal inference. Epidemiology 2006;17:360-372.

29. Hamdy FC, Donovan JL, Lane JA, et al. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 2016;375:1415-24.

30. The CODA Collaborative. A randomized trial comparing antibiotics with appendectomy for appendicitis. N Engl J Med 2020;383:1907-19.

31. Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med 2004;351:971-7.

32. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation 2019;140:e125-51.

33. Wasmann KA, Wijsman P, van Dieren S, Bemelman W, Buskens C. Partially randomised patient preference trials as an alternative design to randomised controlled trials: systematic review and meta-analyses. BMJ Open 2019;9(10):e031151. doi:10.1136/bmjopen-2019-031151

34. Delevry D, Le QA. Effect of treatment preference in randomized controlled trials: a systematic review and meta-analysis. The Patient 2019;12(6):593-609. doi:10.1007/s40271-019-00379-6

35. Gurel O, Mustata Wilson G. Education Is Three Determinants of Health—A Tripartite Classification. arXiv preprint (forthcoming); 2026.

36. Gurel O, Mustata Wilson G, Curley M, Weinstein JN. Public Health Policy Implications of Tripartite Education Determinants of Health. arXiv preprint (forthcoming); 2026.

SUPPLEMENTAL TABLE

Statistical Methods Comparison					
Method	**Causal Inference**	**Handles Crossover**	**Selection Bias**	**NEJM Standard**	**Use**
ITT	Yes—randomization	No—diluted	No	Required baseline	Comparison
IV/2SLS	Yes—LATE	Yes—explicit	Via comparison	CONSORT 2025	PRIMARY
CACE	Yes—compliers	Yes—isolates	Via comparison	CONSORT 2025	CO-PRIMARY
Observational	No—confounded	N/A	Benchmark	Not alone	Bias quantification
***E*-values**	N/A—sensitivity	N/A	Quantifies confounding	Recommended	ESSENTIAL